Experience

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…

Davis Polk advised the joint book-running managers on an SEC-registered offering by General Motors Financial Company, Inc. of $500 million aggregate principal amount of floating-rate senior…

Davis Polk is advising Dyal Capital Partners, a division of Neuberger Berman Group, on its strategic minority investment in Atalaya Capital Management. Dyal will become a passive, non…

Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 4,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by Teladoc, Inc. of $275 million aggregate principal amount of its 3.00% convertible senior notes due 2022…

Davis Polk advised the dealer manager on a cash tender offer by Bristol-Myers Squibb Company for any and all of its 5.875% notes due 2036, 6.125% notes due 2038 and 6.875% debentures due…

Davis Polk advised Hilong Holding Limited on its $250 million Regulation S offering of 7.25% senior notes due 2020. The notes were guaranteed by certain offshore subsidiaries of Hilong. The…

Davis Polk advised the joint global coordinators, joint lead managers and joint bookrunners on a Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.30…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Coach, Inc. of $400 million aggregate principal amount of its 3.000% senior notes…